Longer mirdametinib treatment increased confirmed and deep responses as treatment-related adverse effects declined in neurofibromatosis type 1 tumors.
|Articles|March 9, 2011
- December 2010
- Volume 4
- Issue 12
Web-Based CME Program Started for Rural Oncologists
Author(s)OBTN
A Web-based CME program gives physicians in rural areas free access to clinical research and expert advice on oncology through an e-newsletter.
Advertisement
With a grant from Pfizer, Albert Einstein College of Medicine of Yeshiva University in New York has launched a Web-based CME program to give physicians in rural areas free access to clinical research and expert advice on oncology through an e-newsletter. Nearly a quarter of Americans live in rural areas, where cancer mortality rates are highest. The CME program is expected to provide oncologists with better and earlier access to critical developments in cancer research.
Articles in this issue
over 15 years ago
Medulloblastoma Subtypes Are Different Diseasesover 15 years ago
ASH 2010: Elotuzumab Highly Active in Patients With Advanced Myelomaover 15 years ago
FDA Requests Label Change for Generic DocetaxelAdvertisement
Related to this article
Age, geographic location, transportation barriers, and language and communication barriers may limit patient opportunities to participate in research.
Retrospective data tie longer survival with niraparib maintenance to homologous recombination deficiency after complete primary debulking.
Exploratory BEHOLD-1 data show responses to mocertatug rezetecan in platinum-resistant ovarian cancer across B7-H4 expression levels.
Updated BEHOLD-1 data show mocertatug rezetecan at its selected dose produced lasting responses in platinum-resistant ovarian cancer.
Are we ready to “take that fork in the road” and move palliative/supportive care into routine cancer care?
Misty D. Shields, MD, PhD, answers questions on ADCs, tarlatamab sequencing, first-line maintenance, subtyping, and transformed SCLC.
Keith Flaherty, MD, FAACR, discusses the 2026 AACR Cancer Progress Report and how the oncology field can build on the report’s findings.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Durvalumab Plus Enfortumab Vedotin for Cisplatin-Ineligible MIBC
2
Dr Gleave on Selecting Patients for Perioperative Therapy in High-Risk Prostate Cancer
3
Dr Calais on Individualizing PSMA-Targeted Therapy Sequencing in Prostate Cancer
4
CHMP Recommends Approval of Belzutifan Plus Lenvatinib for Advanced ccRCC After PD-(L)1 Inhibition
5